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Vaccinology aims to understand what factors drive vaccine-induced immunity and 
protection. For many vaccines, however, the mechanisms underlying immunity and 
protection remain incompletely characterized at best, and except for neutralizing 
antibodies induced by viral vaccines, few correlates of protection exist. Recent omics 
and systems biology big data platforms have yielded valuable insights in these areas, 
particularly for viral vaccines, but in the case of more complex vaccines against bacterial 
infectious diseases, understanding is fragmented and limited. To fill this gap, the EC 
supported ADITEC project (http://www.aditecproject.eu/; http://stm.sciencemag.org/
content/4/128/128cm4.full) featured a work package on “Molecular signatures of immu-
nity and immunogenicity,” aimed to identify key molecular mechanisms of innate and 
adaptive immunity during effector and memory stages of immune responses following 
vaccination. Specifically, technologies were developed to assess the human immune 
response to vaccination and infection at the level of the transcriptomic and proteomic 
response, T-cell and B-cell memory formation, cellular trafficking, and key molecular 
pathways of innate immunity, with emphasis on underlying mechanisms of protective 
immunity. This work intersected with other efforts in the ADITEC project. This review 
summarizes the main achievements of the work package.
Keywords: vaccines, biomarkers, immunity and infections, immunity, assays
iNTRODUCTiON
One of the key goals in vaccinology is to understand what factors drive protective immunity 
induced by vaccines. In many cases, the precise mechanisms underlying such immunity remain 
unknown, or at best incompletely characterized. Except for the case of neutralizing antibodies 
induced by viral vaccines, very few correlates of protection exist. The availability of omics technolo-
gies and advanced systems biology big data analytical platforms has enabled large scale analyses 
of vaccine-induced responses. These efforts revealed novel insights into immunity and correlates 
of protection, for example, in the human response to yellow fever and influenza vaccination 
(1, 2). However, for more complex vaccines such as those against bacterial infectious diseases, 
such understanding as yet is mostly lacking.
To fill this gap, EC FP7 supported ADITEC innovative project featured a work package on 
“Molecular signatures of immunity and immunogenicity.” The working group aimed to identify key 
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molecular mechanisms of innate and adaptive immunity during 
effector and memory stages of immune responses following 
vaccination. Specifically, technologies were developed to assess 
the human immune response to vaccination and infection at the 
level of the transcriptomic and proteomic response, T-cell and 
B-cell memory formation, cellular trafficking, and key molecular 
pathways of innate immunity, with emphasis on underlying 
mechanisms of protective immunity. This work was integrated 
with efforts in other sections of the ADITEC project, such as a 
work package on immunity and vaccine-induced responses in 
early life and aging; and work packages on the human response 
to adjuvants in clinical and translational vaccinology.
The following specific issues will be addressed in detail below:
 1. An extended multiplex transcriptomic profiling assay [dual-
color Reverse-Transcription Multiplex Ligation-dependent 
Probe Amplification (dcRT-MLPA)] was developed for bio-
profiling the human immune response following vaccination 
against human infectious diseases, with particular emphasis 
on transcriptomic signatures of innate, adaptive, regulatory, 
inflammatory, and memory responses. Determination of 
optimal responses and dense kinetic transcriptomic response 
measurements will be helpful in optimizing novel immuniza-
tion strategies.
 2. This platform was complemented by global transcriptomic 
gene expression profiling (mRNA as well as micro-RNA) 
following vaccination with a complex vaccine, the live 
recombinant bacille Calmette–Guérin (BCG) (VPM1002), 
which had been tested in infants and adults. Transcriptomic 
analyses were used to dissect novel mechanisms and correlates 
of immunity and safety, with particular emphasis on age and 
temporal changes following vaccination.
 3. Complementing the work on transcriptomics, quantitative 
proteomic profiles were determined using novel platform 
technologies, including hydrogen deuterium exchange 
(HDX) coupled to mass spectrometry (MS). HDX–MS was 
used to define functionally active epitopes and antibodies 
in polyclonal sera following vaccination. Complementing 
studies addressed the role of T follicular helper (Tfh) cells and 
explored their presence in the blood as possible biomarkers of 
protective vaccine efficacy.
 4. A key feature of vaccine-induced immunity is the formation 
of antigen-specific memory T-cells and B-cells, and their 
ability to migrate to the correct tissue sites. New technol-
ogy platforms to analyze human B-cell and T-cell immune 
repertoires, suitable to interrogate large number of B-cells or 
T-cells for the first time, allowed a comprehensive analysis of 
the memory response in all its cellular components. A com-
bination of experimental approaches (antigenic stimulation, 
TCR deep sequencing and cloning of Th1, Th2, and Th17 
memory subsets) allowed the dissection of T-cell subset 
responses, showing that pathogen- or vaccine-induced 
T-cells are functionally heterogeneous and comprise both 
clones polarized toward a single fate, as well as clones whose 
progeny has acquired multiple fates. By immortalizing mem-
ory B-cells from donors upon influenza vaccination, a new 
type of rarely occurring influenza-neutralizing antibodies 
targeting a conserved site in the hemagglutinin (HA) stem 
was found.
 5. To dissect the molecular mechanisms regulating T-cell traf-
ficking at mucosal sites in health and disease, T-cell migration 
in response to chemokines CCL20, CXCL10, and CXCL12 
was assessed. T-cell migration in HIV-1 infection was evalu-
ated as a model of impaired migration to mucosal sites, as 
it is well known that antiretroviral therapy (ART) therapy is 
not able to fully restore complete T-cell repopulation of the 
intestinal mucosa in HIV-1 infected patients. Both CCR6+ 
and CXCR3+ CD4+ T-cells from HIV-1 infected patients, 
albeit expressing the same number of chemokine receptor as 
in healthy individuals, were characterized by an inefficient 
polymerization of actin after receptor triggering, regardless 
of ART therapy. This impairment was also confirmed in a 
macaque SIV infection model. In vivo studies showed that 
persistent immune activation, but not the presence of the 
virus, was responsible for the alterations in the cytoskeleton 
machinery, resulting in altered cellular trafficking to the 
mucosal compartment. This could be redressed by pharma-
cological intervention, restoring effective lymphocyte migra-
tion. These results highlight the importance of evaluating the 
capability of Th cells to reach mucosal niches to support cell 
maturation and functional activity, particularly in individuals 
experiencing chronic immune activation, and thus suggest 
new molecular strategies for improved vaccination.
 6. Activation of innate immunity is key to adjuvant activity and 
expression of vaccine effector mechanisms. Since plasticity 
and polarization are key components of innate immunity, 
key molecular markers of innate immunity were investigated 
in the context of adjuvant activity and expression of vaccine 
effector mechanisms. One focus was on the role of pentraxin 3 
(PTX3), a member of the pentraxin family involved in innate 
resistance, as an endogenous adjuvant in vaccination using 
outer membrane vesicles (OMV) from Neisseria meningitidis 
(Nm) as a model vaccine. In addition, the role of PTX3 in 
innate resistance to pathogens, particularly in urinary tract 
infections was assessed. This work allowed the description 
of the association of PTX3 human genetic polymorphisms 
with susceptibility to infections with Aspergillus fumigatus 
in immunocompromised patients and with uropathogenic 
Escherichia coli. In addition, the role of PTX3 in tissue 
remodeling was defined and novel markers associated with 
macrophage polarization discovered.
Each of these topics will be discussed in more detail, followed 
by a concluding section.
A dcRT-MLPA ASSAY TO iDeNTiFY  
NOveL DiAGNOSTiC, PROGNOSTiC, AND 
PReDiCTive BiOMARKeRS iN ReSPONSe 
TO vACCiNATiON, iNFeCTiON, ACTive 
DiSeASe, AND CURe
Dissecting innate, adaptive, and inflammatory immune signa-
tures underlie the identification of biomarker signatures that can 
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be used to diagnose infection or disease; to predict progression 
toward disease in the infected host; to monitor the efficacy of 
disease treatment; or to predict (in)adequate responsiveness 
to novel or existing vaccines. The latter signatures will greatly 
aid the rational development, testing and evaluation of novel 
vaccines. They may also allow the study of the impact of host 
factors such as age (elderly vs. children), coinfection [HIV, CMV, 
Epstein–Barr virus (EBV), etc.], comorbidity (type 2 diabetes, 
allergic, and inflammatory disorders) or iatrogenic immunosup-
pression (biologicals, other immunosuppressants) on responses 
to vaccines.
To investigate such human immune responses at the tran-
scriptomic level, we have developed a dcRT-MLPA assay (3). 
dcRT-MLPA is a focused gene expression profiling platform that 
has proven suitable to identify, monitor, and validate multicom-
ponent host diagnostic and prognostic/predictive biomarker sig-
natures in many human cohort studies (4). The studies described 
in this article focus on the discovery of diagnostic, prognostic, 
and therapy-responsive biomarker signatures mainly in tubercu-
losis (TB). Genes were selected for inclusion in the dcRT-MLPA 
targeted gene expression profiling platform based on their ability 
to assess various compartments of the human immune response, 
with key roles in inducing and skewing immune reactivity and 
inflammation. This included genes representing adaptive immune 
responses (T/NK/B-cell, Treg, and Th1/Th2/Th9/Th17 and Th22 
responses, cytotoxicity, and cell subset markers); innate immune 
responses (myeloid associated markers and scavenger receptors, 
pattern recognition receptors, and inflammasome components); 
inflammatory and IFN-signaling genes; and genes associated 
with apoptosis, cell growth/proliferation, transcriptional regula-
tors/activators, mitochondrial stress, and inflammation.
Diagnostic Biomarkers
Tuberculosis is a global health problem and the world’s leading 
cause of death from infectious diseases [World Health (5)]. 
One-fourth of the worldwide population is latently infected 
with Mycobacterium tuberculosis (Mtb), the pathogen causing 
TB, while active disease develops in about 5–10% of infected 
individuals. Understanding the differences in immune responses 
between individuals able to control the infection versus those 
who develop active disease, preferably in a preclinical stage, 
would greatly facilitate vaccine development. However, since no 
correlates of protection have been uncovered yet and vaccination 
with BCG mainly contributes to the prevention and control of 
childhood but not adult TB, effective control of the TB pandemic 
still mainly depends on accurate diagnosis and early detection of 
active disease, allowing curative treatment to be initiated before 
TB transmission can occur. Because current immunological 
tools to diagnose TB infection, such as the tuberculin skin test 
and interferon-gamma release assays are not able to distinguish 
between latent TB infection (LTBI) and active TB disease, and have 
poor sensitivity in children and immune-compromised individu-
als, direct ex vivo whole blood RNA expression profiling was per-
formed in genetically and geographically diverse adult, pediatric 
and HIV-infected cohorts to identify biomarkers that can classify 
clinical stages of TB independent of age, HIV status and genetic 
background.
Characterization of the human immune response to Mtb in 
cohorts from South Africa, Malawi, The Gambia, Ethiopia, India, 
and Paraguay identified biomarker signatures that were strongly 
associated with active TB and were strikingly distinct from that 
associated with latent infection or uninfected controls (3, 6–10). 
Although the compiled multicomponent signatures differed to a 
certain extent between study cohorts from different geographic 
origins, the most robust single classifier discriminating between 
active disease and latent infection or uninfected controls was 
FCGR1A [high-affinity IgG Fc receptor 1A (CD64)]. This marker 
is significantly higher expressed in individuals with active TB than 
in those with LTBI regardless of age (8, 10), HIV status (7, 9), or geo-
genetic differences (3, 6, 7). This demonstrates the power of this 
biomarker to classify the different clinical outcomes of exposure 
to Mtb and warrants further analysis of the role of FCGR1A in TB 
pathogenesis.
Biomarkers of the Curative Response  
to Therapy
Multi-, extensive-, and total-drug resistant TB (MDR/XDR/
TDR-TB) continues to emerge and is primarily caused by the 
use of ineffective formulations of drugs (such as use of single 
drugs) and poor adherence by TB patients to the strict 6-month 
drug treatment regimen. Therefore, monitoring early kinetics in 
treatment responses is key to the effective delivery of anti-TB 
treatment (ATT) and to prevent de novo drug resistance.
Longitudinal follow up of TB cases during ATT showed 
that biomarkers that can discriminate active TB from LTBI and 
uninfected controls can also be used to monitor TB treatment 
responses independent of age, HIV status, or genetic background 
(3, 8; Gebremicael et al., forthcoming1). In immune-competent 
adults from The Gambia, gene expression profiles normalized 
over time and were similar to those observed in LTBIs and unin-
fected controls at the end of treatment (6 months) (3). However, 
changes in gene expression levels during ATT showed distinct 
kinetics. The expression levels of a proportion of genes normal-
ized to the expression levels observed in LTBIs within 2 months 
(e.g., BLR1), whereas others reached control levels only after the 
full 6 months of treatment (e.g., FCGR1A). Importantly, in HIV-
coinfected TB patients, transcriptomic profiles of ATT treatment 
responses (including expression of FCGR1A) were identified that 
were not affected by highly active antiretroviral therapy, and that 
normalized to levels observed in HIV+ latently TB infected and 
uninfected controls after completion of ATT (see text footnote 
1). Moreover, in an Indian pediatric cohort, baseline levels of 
BLR1 and FCGR1A displayed a capacity of >70% to predict the 
six month treatment outcome (8). Together, these data suggest 
that FCGR1A could possibly serve as part of a reliable and robust 
predictive signature of the treatment response, and as such help 
optimizing personalized medicine in TB while minimizing de 
novo drug resistance, independent of age, immune status and 
genetic background.
1 Gebremicael GKD, Quinten E, Alemayehu Y, Gebreegziaxier A, Belay Y, et  al. 
Host gene expression kinetics during treatment of tuberculosis in HIV-coinfected 
individuals is independent of HAART therapy (Forthcoming).
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Prognostic Biomarkers
Because most immunocompetent individuals maintain a lifelong 
latent infection with Mtb and active disease develops in only a 
minority of infected individuals, identification of correlates of 
TB progression would substantially contribute to combat the 
TB epidemic. In TB endemic areas, such biomarker signatures 
could identify individuals at risk of developing TB, allowing 
curative treatment to be initiated before TB transmission can 
occur.
Transcriptomic profiling of the immune responses of 
immune-competent adult progressors versus non-TB progres-
sors in a well-characterized TB case-contact platform from The 
Gambia identified—among others—antiapoptotic gene BCL2 as 
a marker that might predict the onset of active disease very early 
after infection (11). BCL2 was significantly lower expressed in 
progressors compared with non-progressors, and dysregulation 
of BCL2 occurred as early as 1 year before progression toward TB 
disease. Corroborating these findings at a cellular level, increased 
levels of apoptosis in effector T-cells were found to constitute a 
risk factor for TB disease progression (12).
In addition, in a retrospective case–control study in The 
Netherlands of a high risk population of HIV-infected drug 
users, IL13 and AIRE were identified as markers correlating 
with progression to TB, months before clinical diagnosis (13). 
Furthermore, transcriptomic profiles of IL13-expressing TB 
cases were strongly enriched for type I IFN related signaling 
genes, suggesting that these genes represent processes that 
contribute to TB pathogenesis in HIV-infected individuals. 
Although the association between IL-13-AIRE and TB progres-
sion could not be validated in independent cohorts of HIV-
negative South African and Gambian adult progressors and 
controls, activation of the interferon response, however, was 
validated as a signature predictive of progression toward active 
disease (14). Using RNA-Seq, a whole blood transcriptomic 
mRNA expression signature was identified in a large prospective 
cohort of LTBI adolescents based on the differential expression 
of 16 human genes (14). Interestingly, also FCGR1A (as well as 
FCGR1B) was again part of the predictive signature, in agree-
ment with the importance of these and other IFN-regulated 
genes in TB pathogenesis.
Once these biomarker signatures have been validated in 
larger cohorts, they will provide an initial platform to improve 
diagnosis of TB, monitor TB therapeutic interventions and 
prospectively identify people at risk of developing TB. More 
importantly, these biomarker signatures may help unravel and 
improve our understanding of protective immunity to TB, which 
is a prerequisite for the development of an effective TB vaccine.
TRANSCRiPTOMe PROFiLeS iN iNFANTS 
vACCiNATeD wiTH ReCOMBiNANT  
BCG vPM1002
The current TB vaccine Mycobacterium bovis BCG prevents 
severe disseminated TB in children, but fails to protect against 
pulmonary TB. The recombinant BCG ΔureC:hly (VPM1002) 
was designed to improve safety and immunogenicity (15). This 
recombinant vaccine was modified to express the membrane-
perturbing listeriolysin (Hly) of Listeria monocytogenes, 
allowing egression of mycobacterial antigens into the cytosol 
for better antigen presentation. Simultaneously, its urease C 
deficiency prevents VPM1002 from neutralizing the acidic 
pH inside the phagosome, which is required for the biological 
activity of Hly (16).
In vitro and animal studies have indicated an improved 
cross-priming and increased apoptosis in VPM1002 infected 
macrophages, resulting in improved vaccine efficacy over 
parental BCG (15, 16). Superior protection by VPM1002 was 
later shown to relate to earlier recruitment of type 1 cytokine 
producing T-cells and a profound capacity to produce type 17 
cytokine responses, which was not seen after BCG vaccination 
(17). Moreover, VPM1002 stimulates enhanced AIM2 inflam-
masome activation, enhancing autophagy and secretion of 
(IL)-1β and IL-18 (18). Experiments with immunodeficient mice 
revealed higher safety of VPM1002 as compared with parental 
BCG. Enhanced safety of VPM1002 is also illustrated by a lower 
incidence of abscess formation in immunized infants (19).
VPM1002 has now completed phase I clinical trials in 
healthy adults (19, 20) and a phase IIa trial in South African 
newborns. It is currently undergoing phase II trial assessment 
in HIV-exposed neonates (NCT01479972). Within the ADITEC 
project we have generated gene expression profiles from infants 
participating in the phase IIa trial. Two groups of 11 neonates 
each receiving either VPM1002 or parental BCG were included, 
and gene expression profiles were analyzed from samples taken 
at the time of immunization and at weeks 2, 6, 12, 18, and 26 
postvaccination. Safety and immunogenicity data from this 
clinical trial revealed that safety parameters for VPM1002 and 
the parental BCG strain are comparable. Both vaccines induced 
IFNγ responses, while VPM1002 vaccination in addition resulted 
in an increased proportion of IL-17 producing CD8 T-cells (19).
The gene expression profiles that were generated showed 
a substantial variability in responses between individuals 
(Figure  1A). Following vaccination early after birth, dramatic 
changes in the gene expression profiles over time were observed 
in both groups. The most pronounced changes were associated 
with upregulation of immunoglobulin-related genes, which 
likely reflects the maturation of the immune system in infants. 
In a direct comparison between the groups vaccinated with 
parental BCG and VPM1002, we did not observe any significant 
differences in gene expression at any of the time points analyzed. 
Most likely, differences in gene expression induced by the two 
vaccines, if any, are too small to be detected and may be obscured 
by the pronounced changes over time. Second, this study was 
set up as a safety trial with a limited number of individuals. 
As a consequence, the gene expression analysis was statistically 
underpowered.
Therefore, we harnessed the power of gene modules, using a 
new bioinformatics tool called “tmod” (J. Weiner https://cran.r-
project.org/web/packages/tmod/index.html) to calculate enrich-
ments in genes associated with particular biological responses. 
Results from this analysis indicated subtle functional differences 
between the vaccination groups that could not be detected at 
the single gene level (Figure  1B). For example, the VPM1002 
FiGURe 1 | Gene set enrichment results generated with the tmod R package. (A) Enrichment in gene modules in each individual at 26 weeks postvaccination 
compared with baseline. (B) Gene set enrichment in both groups and between the groups at different time points compared with baseline. Red and blue indicate 
the proportion of genes in a particular module that is upregulated or downregulated respectively. Width of each box relates to its effect size, while brighter colors 
indicate lower p-values. Panel (B) represents a selection of a larger number of enriched gene modules.
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vaccinated group showed earlier and more pronounced changes 
in genes involved in T-cell activation. Similarly, a prolonged 
enrichment in myeloid/monocyte-associated genes could be 
observed in the VPM1002 group (Figure 1B). In a direct com-
parison between the groups, we did observe a weak enrichment 
suggesting a slightly stronger T-cell activation in the first weeks 
following VPM1002 immunization. Also, a more pronounced 
downregulation of PAX3 target genes and pro-inflammatory 
cytokine and chemokine expression in the VPM1002 group, 
although none of these enrichments were statistically significant 
(Figure 1B).
NOveL TeCHNOLOGieS FOR ePiTOPe 
MAPPiNG FOR vACCiNe DeSiGN, AND 
eXPLORATiON OF Tfh CeLLS AS NOveL 
BiOMARKeRS
The analysis of the B-cell repertoire could not be considered 
complete if the fully sequenced IgG are not functionally char-
acterized, quantified in the serum, and the epitopes recognized 
are not defined. All this provides essential information that can 
be used to guide vaccine design and optimization, eventually to 
predict vaccination efficacy and its duration. Considering that 
the majority of the functional B-cell epitopes are discontinuous 
non-linear epitopes having 3D-conformational structures, it is 
important to apply methodologies able to decipher these some-
times complex structures.
We used HDX coupled to MS to allow the mapping of confor-
mational epitopes (21–27). The approach was also compared with 
the most sophisticated and available approaches such as protein 
chip (26, 27), phage display (21, 26, 27), X-ray (21), and cryo-EM 
(24, 25). Modern HDX–MS is more straightforward, rapid, and 
routine than in the past. As a result, the breadth of applications 
of the method, including epitope mapping, has expanded (28). 
HDX–MS relies upon the rapid exchange of backbone amide 
hydrogen for deuterium when a protein is diluted into a deuter-
ated buffer. Each exchange event increases the protein mass of 
1  Da that can be monitored by MS. Epitope mapping through 
HDX is based on differential rates of deuterium incorporation 
by the antigen when it is bound or not with a specific mAb (29). 
When an antigen–antibody complex is formed, the interface 
between the two components can occlude solvent, thereby 
reducing the exchange rate due to the action of solvent steric 
exclusion. Deuterium incorporation of the free antigen and of 
the antigen–mAb complex is compared and antigen sequences 
that present reduced exchange kinetics when the antigen is bound 
to mAb are highlighted as potential epitopes.
In a first phase, we probed the binding between mAb 12C1 
and fHbp, using hybrid approaches including peptide arrays, 
X-ray crystallography, phage display, and HDX–MS, evidencing 
that HDX–MS, although not the highest resolution method, is 
the most effective in providing nearly complete information 
about the structure of epitopes (21). The approach has sufficient 
resolution to recognize fHbp overlapping epitopes with different 
functional properties (22). It was also successfully applied to 
map epitopes from NadA (23, 26) and NHBA (27), the two other 
protective epitopes of the vaccine against group B meningococ-
cus, Bexsero. Hybrid approaches making use of HDX–MS and 
electron microscopy also evidenced the power of HDX–MS to 
map viral antigen epitopes of CMV gH–gL complex. In addition, 
to better characterizing the immune response to vaccination 
and to support antigen design, this method that speeds up the 
elucidation of recognized epitope will contribute to increase the 
FiGURe 2 | Identification of human CD4+ memory T-cell subsets based on 
the differential expression of chemokine receptors.
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number of available structures of antigens and antigen–antibody 
complexes, opening new possibilities for the development of 
novel tools that might reliably predict protective epitopes.
iNFLUeNZA-SPeCiFiC CiRCULATiNG 
T-CeLL SUBSeTS AS eARLY PReDiCTORS 
OF SPeCiFiC ANTiBODY ReSPONSeS
Development of vaccines is a long endeavor requiring long 
and expensive clinical trials to prove the efficacy of vaccines in 
the relevant target populations. The availability of biomarkers 
predicting protection or predicting protective immune respon-
siveness may accelerate the development of vaccines.
T follicular helper cells are a CD4+ T-cell subpopulation that 
is identifiable in lymph nodes and tonsils. Tfh cells are special-
ized in providing help to B-cells (30–32). The identification of 
a circulating counterpart of the Tfh subset in the blood (33, 34) 
would allow the measurement of these cells following vaccina-
tion, which may help defining markers predicting vaccine effi-
cacy. Therefore, the question was to investigate whether IL-21+ 
CD4+ T-cells induced by specific vaccination were detectable in 
human blood, if and how vaccination modulated their frequency, 
and whether their expansion correlated with increased titers 
of functional antibodies. Indeed, following vaccination with 
MF59-adjuvanted avian H5N1 vaccine, H5N1-specific IL-21+ 
CD4+ T-cells were detectable in the blood, expanded after vac-
cination and accumulated in the CXCR5−ICOS1+ subset. The 
rise of vaccine-specific ICOS1+ IL-21+ CD4+ T-cells appeared 
to predict the postvaccination increase of functional antibodies 
in these vaccines. Finally, circulating CXCR5−ICOS1+ CD4+ 
T-cells contained increased numbers of T-cells able to help 
influenza-specific B-cell differentiation, such that they differ-
entiated in vitro into antibody-secreting cells in a manner that 
was dependent on IL-21− and ICOS1 (35). More recent studies 
have confirmed these findings and have also shown that the early 
expansion of cells with a Tfh phenotype predicts the long term 
persistence of neutralizing antibodies against influenza virus 
(36). Thus, the expansion of antigen-specific ICOS1+ IL-21+ 
CD4+ T-cells in the circulation may represent an early predic-
tor of a vaccine’s ability to stimulate vaccine-specific immunity 
and a useful surrogate marker of a vaccine’s immunogenicity in 
human beings.
HeTeROGeNeiTY OF MeMORY  
CD4+ T-CeLLS iNDUCeD BY  
PATHOGeNS OR vACCiNeS
CD4+ T helper cells are crucial players in the adaptive immune 
response, contributing to protection against a wide range of 
pathogens through the functional regulation of other immune 
and non-immune cell types. CD4+ T helper cells are character-
ized by functional diversity that has evolved to provide the most 
appropriate type of response against different classes of pathogens 
in different tissues (37). Th1  cells produce IFNγ, express the 
transcription factor T-bet and, through the activation of mac-
rophages, contribute to immunity against intracellular pathogens. 
Th2 cells produce IL-4, IL-5, and IL-13, express the transcription 
factor GATA-3 and, through the activation of eosinophils and 
mast cells, contribute to protection against helminth parasites. 
Th17  cells produce IL-17A, IL-17F, and IL-22, express RORγt 
and together with neutrophils, mediate protection against fungi 
and extracellular bacteria. Th1, Th2, and Th17 cells differ also in 
the expression of chemokine receptors that control their homing 
ability, a property that is coordinately obtained during the process 
of T-cell differentiation (38). CCR5 and CXCR3 are expressed by 
Th1 cells, CCR4, CCR3, and CRTh2 by Th2 cells, and CCR6 and 
CCR4 by Th17 cells. While the role of distinct subsets of CD4+ 
T-cells in protection against different types of pathogens has long 
been recognized, it has been unclear whether a given vaccine or 
pathogen will induce a single type of T-cells and whether a single 
naive T-cell challenged by a pathogen or by a vaccine may acquire 
multiple T-cell fates.
We combined antigenic stimulation, TCR deep sequencing 
and cloning of human Th1, Th2, and Th17 memory subsets, 
to study the distribution and TCR repertoire of pathogen- and 
vaccine-specific T-cells in immune donors (39). We found that 
memory T-cells induced by Candida albicans are present at 
high frequency in a CCR6+ compartment, which comprises 
Th17 and a subpopulation of Th1 cells co-expressing T-bet and 
RORγt (defined as Th1*), and at low frequency in a CCR6− 
compartment, which comprises classical Th1 and Th2 cells (40) 
(Figure  2). We could then demonstrate, using next-generation 
TCR Vβ sequencing, that multiple different clonotypes were 
present in more than one subset and, in several cases even in all 
subsets, whereas by contrast other clonotypes were found only 
in one particular subset. We also studied tetanus toxoid (given 
with alum as adjuvant) vaccine-induced memory T-cells. Also in 
this case, TCR Vβ sequencing revealed a high level of clonotype 
sharing among Th1, Th2, Th1*, and Th17 subsets, with multiple 
different clonotypes represented in three and even all four subsets. 
By contrast, Mtb-specific memory T-cells in healthy donors were 
highly enriched in the Th1* subsets, with some specific T-cells 
present in the Th17 subset. In contrast to what was observed 
for C. albicans, however, only very few clonotypes were shared 
between Mtb-specific Th1* and Th17. Taken together, our results 
indicate that human T-cells induced by pathogens or vaccines are 
functionally heterogeneous and comprise both clones polarized 
toward a single fate, as well as clones whose progeny has acquired 
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multiple fates. The highly significant intraclonal heterogeneity 
observed in this work further supports the one cell-multiple 
fates model of CD4 T-cell differentiation; furthermore these 
data reveal T-cell plasticity in the context of the human T-cell 
immune response. An important question that this study raises 
is whether the induction of functionally diverse T-cell subsets 
by for instance a vaccine is advantageous for the host. Clearly, 
defective induction of the correct type of Th cell response may 
increase susceptibility to infections, while the induction of a 
wider spectrum of different T-cell types, including effector and 
memory T-cells with different migratory abilities would enlarge 
the range of differentiated precursors that the host could recruit 
and expand whenever necessary.
A New CLASS OF RARe iNFLUeNZA-
NeUTRALiZiNG ANTiBODieS TARGeT  
A CONSeRveD SiTe iN THe HA STeM
By immortalizing memory B-cells from donors upon influ-
enza vaccination, a new type of rarely occurring influenza- 
neutralizing antibodies, targeting a conserved site in the HA stem 
was found.
High throughput cellular screens have been developed and 
used to isolate potently and broadly neutralizing antibodies 
against a plethora of pathogens. We used EBV in the presence 
of CpG to immortalize memory B-cells with high efficiency, and 
screened culture supernatants for the presence of the desired 
antibodies using multiple assays based on binding or viral 
neutralization. Using this approach, we studied the antibody 
response to influenza HA. The neutralizing antibody response 
is dominated by antibodies binding the most variable part of 
the HA, the globular head, which is undergoing antigenic drift 
continuously. As a consequence, most of anti-head antibod-
ies, which are detected using the classical hemagglutination 
inhibition assay, neutralize only a few isolates within a given 
subtype. We and others have previously described hetero-
subtypic neutralizing antibodies that can bind and neutralize 
different influenza virus subtypes, comprising group 1 viruses 
and even group 1 and group 2 viruses (41). The broadly neu-
tralizing antibodies target a conserved site in the HA stem and 
use a particular VH gene, VH1-69. These antibodies are highly 
mutated, and they are produced by some but not all individuals. 
This would suggest that a series of somatic mutations may be 
necessary for the development of such antibodies. To address 
the developmental pathway of anti-stem antibodies, we isolated, 
from a single donor, 197 VH1-69+ anti-stem antibodies. Using 
sequence information, we performed a genealogical analysis 
to reconstruct the developmental pathways of a number of the 
VH1-69 clones. We identified key elements which were required 
for affinity maturation. In all cases tested, the binding to HA was 
exclusively dependent on the mutated VH, while the light chain 
did not play a significant role since it could be substituted by 
irrelevant L chains. Strikingly, in most clones, affinity matura-
tion was achieved through a single somatic mutation leading 
to a proline to alanine substitution at position 52a in HCDR2. 
This mutation was the first to occur in the B-cell clone and was 
sufficient to confer high-affinity binding to the selecting H1 anti-
gen. This observation is consistent with rapid affinity maturation. 
Unexpectedly, however, further favorable mutations continued 
to accumulate, which further increased the breadth of antibody 
reactivity while making both the initial mutations functionally 
redundant. We also determined that phenylalanine 54, which 
was characteristic of all antibodies, was an essential binding 
residue. Interestingly, this position is polymorphic and individu-
als lacking a phenylalanine 54 allele did not produce VH1-69 
antibodies to the HA stem. Finally, all VH1-69 anti-stem anti-
bodies shared a 13-aminoacid-long HCDR3 with a tyrosine at 
position 98. This study defines VH1-69 polymorphism, HCDR3 
sequence constraints and an individual somatic mutation as 
the three requirements involved in the generation of broadly 
neutralizing antibodies. It also reveals an hitherto unknown and 
unexpected redundancy in process of affinity maturation (42).
MOLeCULAR MeCHANiSMS 
ReGULATiNG T-CeLL TRAFFiCKiNG  
AT MUCOSAL SiTeS iN HeALTH AND 
DiSeASe: CHRONiC iMMUNe ACTivATiON 
DAMPeNS LeUKOCYTe TRAFFiCKiNG 
AND CALLS FOR NOveL vACCiNATiON 
STRATeGieS
The homing of leukocytes in general, and antigen-specific 
T-cells in particular, to peripheral tissues, mucosal sites, and 
secondary lymphoid organs is controlled, among others, by the 
local production of chemokines, the expression of chemokine 
receptors on the cell surface, and an efficient cytoskeleton 
machinery (43, 44). The characterization of the surface expres-
sion of the different chemokine receptors on T-cells has guided 
the discovery of different T helper cell subsets and is still 
a precious tool for the characterization of novel functional 
subsets. Nevertheless, scanty information is available on the 
influence that pathological conditions can have on the activity 
of chemokine receptors, even if their expression on the T-cell 
surface remains unaltered compared with healthy individu-
als. In health and disease, the microenvironment can further 
control cell migration, by releasing factors that cooperate with 
chemokines for enhancing cell responses (45–49), or by pro-
ducing natural chemokine antagonists that block chemokine-
induced activities (49). In addition, to the proteins produced by 
the microenvironment, systemic chronic immune activation can 
dampen T-cell responses to chemokines (50). HIV-1 infection 
is a clear example for this phenomenon, since chronic immune 
activation due to microbial translocation has been associated 
with poor T-cell repopulation of the intestinal mucosa during 
ART (51, 52). CD4+ T-cells expressing the chemokine receptors 
CCR6+ and/or CXCR3+ can traffic to the intestine in response 
to CCL20 and to IFNγ-induced chemokines, to help maintain 
the integrity of the mucosal barrier (53). In HIV-1 infected 
patients, regardless of ART therapy, CD4+ T-cells inefficiently 
migrate after chemokine triggering, due to an unproductive 
polymerization of actin (50). Interestingly, an in  vivo model 
8Haks et al. Biosignatures of Immunity and Vaccination 
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1563
of sustained toll-like receptor (TLR) 7 triggering with R848 
recapitulated chronic immune activation, lymphoid system 
disruption, and poor response to chemokines as observed in 
HIV-1-mediated pathology (50, 54). It is indeed the persistent 
immune activation, and not the presence of the virus, that is 
causing the impaired response to chemokines. This deficiency 
is due to alterations in the cytoskeleton machinery that could 
be used as a marker to assess T-cell anergy caused by TLR7 
triggering (55). Pharmacological intervention acting on the 
cytoskeleton can restore a proper response to chemokines 
both in vitro and in vivo (50) and represents novel therapeutic 
approaches, which are also amenable for combination with 
other therapies such as ART. It will be important to verify 
indeed whether such new immunotherapeutic interventions, 
aimed at dampening chronic immune activation during HIV-1 
infection (56), result in efficient restoration of leukocyte migra-
tion. This is of particular interest since chronic activation of 
the immune system is not only present in HIV-1 infection, 
but is also a signature of other persistent infections as well as 
autoimmunity. Moreover, inflammation is a major component 
of senescence and aging-associated pathology (57–59). The 
study of frail cohorts of individuals and patients will identify 
those in need of receiving novel vaccine formulations that 
would improve the ability of leukocytes to migrate to the site of 
vaccination and later also during infection to properly mount an 
effective immune response.
DiSSeCTiNG iNNATe iMMUNiTY AND 
DeveLOPiNG TOOLS FOR iNNATe 
iMMUNe BiOPROFiLiNG
Activation of an innate inflammatory response is a key step in the 
mechanisms of action of adjuvants. Gene expression profiling 
of the mouse muscle injected with different adjuvants revealed 
modulation of a cluster of innate immunity genes, including par-
ticularly: cytokines, cytokine receptors, chemokines, adhesion 
molecules, and proteins involved in host–pathogen interactions 
(60). In particular the long PTX3, a soluble pattern recognition 
molecule identified in the 1990s (61), was among the over 1,000 
genes upregulated by adjuvant treatment. PTX3 is classified 
as a member of the pentraxins, a family of highly conserved 
molecules characterized by a unique multimeric structure (62, 
63; Garlanda et al., forthcoming2). Based on the sequence of the 
composing promotors, two subfamilies can be distinguished: 
short and long pentraxins. C-reactive protein (CRP) and serum 
amyloid P component are prototypic short pentraxins, by con-
trast PTX3 is a prototypic long pentraxin subfamily member.
Despite their sequence homologies, CRP and PTX3 differ 
in molecular structure, gene organization and cellular sources. 
CRP is produced only by the liver in response to IL-6 while PTX3 
is produced locally and more rapidly by myeloid and stromal 
cells in response to primary pro-inflammatory cytokines (IL-1β 
2 Garlanda C, Bottazzi B, Magrini E, Inforzato A, Mantovani A. PTX3, a key com-
ponent of humoral innate immunity at the interface between defense and tissue 
remodeling. Physiol Rev (Forthcoming).
and TNF-α) and ligation of TLRs. In addition, PTX3 is stored 
in neutrophils-specific granules, from which it is promptly 
released upon microbial recognition (63). From a functional 
point of view, PTX3 is endowed with multifunctional proper-
ties at the crossroad of inflammation, innate immunity, tissue 
remodeling, and female fertility. Of note, PTX3 plays an essen-
tial non-redundant role in resistance to selected microbes. The 
protein has antibody-like properties, binding selected patho-
gens (i.e., A. fumigatus, Pseudomonas aeruginosa, and more) 
and conserved microbial moieties (outer membrane protein A 
from Klebsiella pneumoniae; HA glycoprotein from influenza 
virus), and facilitating phagocytosis of recognized microbes in 
a manner dependent on Fcγ receptors and complement (64, 65). 
Moreover, PTX3 orchestrates complement activity (66) and, by 
regulating complement-dependent tumor promoting inflam-
mation, can act as an extrinsic oncosuppressor gene in murine 
and human tumors (67). Finally, recent results obtained in dif-
ferent models of tissue damage highlighted a non-redundant 
role of PTX3 in remodeling and repair of tissue via its interac-
tion with fibrin (68). This further supports the evidence that 
the recognition of matrix and microbial components is shared 
ancestral features of the humoral arm of the innate immune 
system.
In view of the upregulation of PTX3 by selected adjuvants 
we investigated the role of this protein in the antibody response 
using a well-known model of vaccination with OMV from Nm. 
We found that PTX3 binds Nm as well as OMV derived from Nm, 
exerting a protective role in a model of infection with Nm in the 
infant rat. Ptx3-deficient mice vaccinated with OMV without any 
adjuvant developed a lower antibody response compared with 
WT mice. In addition, co-injection of PTX3 enhanced the anti-
body response, especially in ptx3-deficient mice. Recognition 
of the antigen is essential for the effect exerted by PTX3, since 
immunization with an antigen not recognized by PTX3, such as 
ovalbumin, induced similar response in WT and ptx3−/− mice 
(69). This observation was confirmed by further investigations 
showing that ptx3−/− mice produced lower levels of IgM in 
response to administration of Pneumovax, a human vaccine 
containing capsular polysaccharide from multiple Streptococcus 
pneumoniae (Sp) serotypes (70). Similarly, ptx3−/− mice pro-
duced less antibodies following immunization with PR8 influ-
enza A virus, which is also recognized by PTX3 (71), and in both 
cases PTX3 administration restored the response. Searching for 
an explanation of these effects, it has been found that PTX3 was 
released by B helper neutrophils (NBh) and bound to B-cells 
located in the marginal zone (MZ) in the spleen. NBh are an 
innate-like subset of antibody-producing cells positioned at the 
interface of the adaptive immune system and the circulation. 
The interaction between PTX3 and MZ-B-cells activated signals 
that were independent of FcγR but triggered class-switching 
from IgM to IgG. PTX3 promoted MZ-B-cell differentiation 
into extrafollicular plasmablasts and plasma cells, and enhanced 
IgM and IgG responses to the encapsulated bacterium Sp, or 
after immunization with capsular polysaccharides or bacte-
rial carbohydrates. These results indicate that the humoral 
pattern recognition molecule PTX3, produced in response to 
pro-inflammatory cytokines or selected adjuvants, may amplify 
FiGURe 3 | Pentraxin 3 (PTX3) as endogenous adjuvant. PTX3 is locally produced at sites of infection or inflammation by myeloid cells in response to primary 
pro-inflammatory cytokines and toll-like receptor (TLR) engagement. In addition, the PTX3 gene is rapidly upregulated after treatment with selected adjuvants (MF59; 
CpG). PTX3 plays essential roles in the immune response to recognized pathogens: it is an active player in the innate immune response to microbes, acting as an 
opsonin and enhancing phagocytosis. Moreover, PTX3 is involved in immunoglobulin production and class switching from IgM to IgG, promoting humoral adaptive 
responses. The function of PTX3 as a bridge between the humoral arms of the innate and adaptive immune systems is in agreement with a role as endogenous 
adjuvant.
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effective adaptive antibody responses that are induced by 
antigens recognized by PTX3, thus serving as an endogenous 
adjuvant (Figure 3).
The data outlined above provide a rationale to evaluate 
whether PTX3 could be a correlate of the shaping of the immune 
response induced by adjuvants in humans. In collaboration with 
D. J. Lewis and G. Del Giudice, PTX3 and CRP plasma levels 
were measured in a cohort of individuals injected with placebo 
or with licensed influenza vaccines adjuvanted or not. This 
study received ethical approval from London—Surrey Borders 
Research Ethics Committee (REC Ref: 13/LO/0044) and was reg-
istered on ClinicalTrials.gov before enrollment (NCT01771367). 
Preliminary unpublished results evidenced an increase in PTX3 
plasma levels at early time points in individuals injected with the 
adjuvanted vaccine, confirming in humans the effects on PTX3 
gene upregulation initially observed in mice (60). In addition, 
after immunization with an adjuvanted vaccine we observed an 
earlier induction of PTX3 (peak at 24 h postinjection) compared 
with CRP (peak at 48  h postinjection), likely due to the local 
expression of PTX3 versus the systemic production of CRP.
Several single nucleotide polymorphisms (SNPs) have 
been described in the human PTX3 gene, mainly located in its 
non-coding regions with the only exception of one exonic SNP 
causing an amino acid variation in position 48 (Asp48Ala). PTX3 
haplotypes are associated with increased susceptibility to lung TB 
(72), P. aeruginosa infections in cystic fibrosis Caucasian patients 
(73), A. fumigatus infections in bone marrow transplanted 
patients (74), and urinary tract infections (75). Results in a large 
cohort of patients with fungal infections after solid organ trans-
plantation (76) and in 2,609 bone marrow transplanted patients 
and their donor pairs (77) further reinforced the association 
of PTX3 gene SNPs and susceptibility to fungal infection. The 
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protection-associated haplotypes were also associated with higher 
PTX3 protein expression and circulating levels (74, 76), support-
ing an active role of PTX3 as non-redundant player involved in 
the innate defense against recognized pathogens.
In summary PTX3, a molecule of the innate immune system, 
produced in response to pro-inflammatory mediators, not only 
acts as an antibody-like molecule, recognizing pathogens and 
promoting their removal but also helps in antibody production 
by adaptive immunity, acting as endogenous adjuvant. This is 
schematically depicted in Figure 3.
CONCLUDiNG ReMARKS
Understanding the factors that are critical for the induction 
of protective immunity by vaccines is key for the rational 
development of novel vaccines and to optimize vaccine efficacy. 
Within the ADITEC work package “Molecular signatures of 
immunity and immunogenicity,” the aim was to identify key 
molecular mechanisms of innate and adaptive immunity fol-
lowing vaccination and to uncover correlates of protection at 
the transcriptomic, proteomic and cellular level.
Transcriptomic profiling identified IFN-inducible gene 
FCGR1A as one of the most robust and consistent single bio-
markers that could serve as part of reliable predictive signatures 
discriminating active TB disease from latent infection, iden-
tifying individuals at risk of developing TB, and monitoring 
TB treatment response kinetics. Such signatures are useful 
in stratifying risk groups for preventive treatment or clinical 
vaccine testing, as well as minimizing treatment duration and 
preventing possible de novo drug resistance, independent of 
age, immune status and genetic background. By contrast, when 
comparing transcriptome profiles between infants vaccinated 
with parental or recombinant BCG VPM1002 to unravel the 
mechanisms underlying superior protection against TB by 
VPM1002, differences at the single gene level could not be 
detec ted. Therefore, a new bioinformatics tool (tmod) was used 
to calculate enrichments in genes, uncovering more pronounced 
changes in T-cell activation and myeloid/monocyte-associated 
genes in the VPM1002 vaccinated group. Complementing the 
work on transcriptomics, HDX–MS was used to determine 
quantitative proteomic profiles and was successfully applied 
to define functionally active epitopes and antibodies in poly-
clonal sera following vaccination for various bacterial vaccines.
At the cellular level, early expansion of vaccine-specific CD4+ 
Tfh cells in peripheral blood was found to predict long term 
persistence of neutralizing antibodies against influenza virus, 
suggesting this to be a possible biomarker of protective vaccine 
efficacy. In addition, it was observed that vaccine-induced human 
CD4+ T-cells are functionally heterogeneous and comprise not 
only clones polarized toward a single fate but also clones that fit 
the one cell-multiple fates model of CD4 T-cell differentiation. 
This suggests that inducing broader range of effector and memory 
T-cells with broad and different functional properties would 
benefit the host by expanding the number of options to respond 
to pathogens. Parameters affecting the ability of leukocytes to 
properly migrate to the site of vaccination and mount an effective 
immune response were also investigated. Interestingly, persistent 
immune activation caused impaired T-cell trafficking at mucosal 
sites, which was due to alterations in the cytoskeleton machinery. 
Pharmacological intervention acting on the cytoskeleton could 
restore a proper response to chemokines, calling for novel vacci-
nation strategies in frail individuals. Finally, PTX3 was identified 
as a molecule produced by the innate immune system in response 
to pro-inflammatory mediators and was shown to be involved in 
the innate defense against recognized pathogens. PTX3 functions 
as an endogenous adjuvant, bridging the humoral arms of the 
innate and adaptive immune systems.
In summary, within the ADITEC work package “Molecular 
signatures of immunity and immunogenicity,” dissecting the 
human innate and adaptive immune response to vaccination and 
infection identified not only novel biomarker signatures at the 
transcriptomic, proteomic, and cellular level that could serve as 
potential correlates of risk and of protection but also uncovered 
novel markers and mechanisms underlying protective immunity. 
Validating and further expanding on these findings will advance 
our understanding of protective immunity, which is a key step 
toward the development of effective novel vaccines.
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